CARM (CARISMA Therapeutics) FCF Margin %: 4.22% (As of Sep. 2025)


What is CARISMA Therapeutics FCF Margin %?

CARISMA Therapeutics CARM +1.25% FCF Margin % is 4.22% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, CARISMA Therapeutics ranks better than 56.56% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CARISMA Therapeutics's Free Cash Flow for the three months ended in Sep. 2025 was $1.91 Mil. CARISMA Therapeutics's Revenue for the three months ended in Sep. 2025 was $45.25 Mil. Therefore, CARISMA Therapeutics's FCF Margin % for the quarter that ended in Sep. 2025 was 4.22%.

As of today, CARISMA Therapeutics's current FCF Yield % is -6,612.09%.

The historical rank and industry rank for CARISMA Therapeutics's FCF Margin % or its related term are showing as below:

CARM' s FCF Margin % Range Over the Past 10 Years
Min: -551.71   Med: -305.83   Max: -42.59
Current: -42.59

During the past 5 years, the highest FCF Margin % of CARISMA Therapeutics was -42.59%. The lowest was -551.71%. And the median was -305.83%.

CARM's FCF Margin % is ranked better than
56.56% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs CARM: -42.59

CARISMA Therapeutics FCF Margin % Related Terms

CARISMA Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics FCF Margin % Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
0.00 0.00 -99.41 -551.71 -305.83

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -384.64 -228.63 -269.97 0.00 4.22

CARM vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's FCF Margin % falls into.


CARISMA Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-60.04/19.632
=-305.83 %

CARISMA Therapeutics's FCF Margin for the quarter that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=1.908/45.25
=4.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 4.22% mean?
CARISMA Therapeutics (CARM) has a FCF Margin % of 4.22% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #417 out of 960 companies in the Biotechnology industry, placing it in the top 43.4%.
Is CARISMA Therapeutics' FCF Margin % too high?
CARISMA Therapeutics' current FCF Margin % is 4.22%. Based on the distribution chart, CARISMA Therapeutics ranks #417 out of 960 companies in the Biotechnology industry, which is above the industry midpoint.
How does CARISMA Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #417 out of 960 companies for FCF Margin %. This puts CARISMA Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current FCF Margin % is 4.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current FCF Margin % is 4.22%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current FCF Margin % is 4.22% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.